
News|Articles|October 1, 2004
Rofecoxib voluntarily withdrawn from market due to cardiovascular risk
Rofecoxib voluntarily withdrawn from market due to cardiovascular risk
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement

















































